Tracy Rose, MD, discusses the promising outlook of the current bladder cancer space.
Tracy Rose, MD, MPH, assistant professor of Medicine in the Division of Oncology at the University of North Carolina at Chapel Hill, discusses the promising outlook of the current bladder cancer space.
Though cisplatin-based chemotherapy as the standard-of-care for muscle-invasive bladder cancer prior to surgery with radical cystectomy works, researchers are always aiming to come up with new and innovative treatments. According to Rose, investigators are currently working on how to avoid surgery altogether for these patients.
As of now, there are various large, randomized studies ongoing, including RETAIN-2 (NCT02710734) and A031701 (NCT03609216), which look to create greater responses in this patient population.
Rose notes that understanding which patients should or should not get combination therapies, immunotherapies, or other targeted therapies is key in gaining a further understanding of what works. Additionally, the field is moving quickly towards personalized care and finding what treatment works best for each individual patient.
Transcription:
0:08 | There's lots of big, randomized studies. All of the current combination studies right now are using gemcitabine and cisplatin backbone as what we're combining immunotherapy with, and I think some of those studies should consider using other backbones, like the dose-dense regimens, to see if perhaps that can give us even greater responses or be better partners for immunotherapy.
0:34 | Figuring out which patients should get combination therapies, and which shouldn't, figuring out which patients should get immunotherapy and which shouldn't, should get other targeted therapies that have slightly higher response rates [is exciting]. I think that is really where the field is going and sort of personalized care and not a one size fits all for either perioperative therapy or metastatic therapy of sort of what treatment is really best for you.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Immunotherapy Meets the Frontline in Bladder Cancer, Leaving Gaps in Later Lines
June 24th 2024Recent data, trials, approvals, and presentations during the 2024 American Urological Association Annual Meeting paint a positive treatment landscape for patients with metastatic and non–muscle-invasive bladder cancer.
Read More
High CR Rate in BCG-Unresponsive NMIBC With Cretostimogene Grenadenorepvec/Pembro
June 5th 2024A high complete response rate was achieved in patients with BCG–unresponsive NMIBC using the combination of cretostimogene grenadenorepvec and pembrolizumab, according to final phase 2 CORE-001 trial results.
Read More